Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes

Drug Metabolism and Disposition

Volumn 24, Issue 10, 1996, Pages 1081-1087

  Karam, W G ^a   Goldstein, J A ^a   Lasker, J M ^b   Ghanayem, B I ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYOMEPRAZOLE; ANTIULCER AGENT; CYTOCHROME P450 ISOENZYME; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; OMEPRAZOLE SULFONE; OXYGENASE; RECOMBINANT PROTEIN; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 0029858783     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. S. Holt and C. W. Howden: Omeprazole: overview and opinion. Dig. Dis. Sci. 36, 385-393 (1991).
2. P. N. Maton: Omeprazole. N. Engl. J. Med. 324, 965-975 (1991).
3. D. R. Sohn, K. Kobayashi, K. Chiba, K.-H. Lee, S.-G. Shin, and T. Ishizaki: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J. Pharmacol. Exp. Ther. 262, 1195-1202 (1992).
4. 14C]omeprazole in humans. Drug Metab. Dispos. 17, 69-76 (1989).
5. C.-G. Regardh, T. Andersson, P. O. Lagerstrom, P. Lundborg, and I. Skanberg: The pharmacokinetics of omeprazole in humans: a study of single intravenous and oral doses. Ther. Drug. Monit. 12, 163-172 (1990).
6. C. G. Regardh, M. Gabrielsson, K. J. Hoffman, I. Lofberg, and I. Skanberg: Pharmacokinetics and metabolism of omeprazole in animals and man: an overview. Scand. J. Gastroenterol. 20, (Suppl. 108) 79-94 (1985).
7. T. Andersson, J. O. Miners, M. E. Veronese, W. Tassaneeyakul, U. A. Meyer, and D. J. Birkett: Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36, 521-530 (1993).
8. T. Andersson, J. O. Miners, M. E. Veronese, and D. J. Birkett: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 37, 597-604 (1994).
9. G. R. Wilkinson, F. P. Guengerich, and R. A. Branch: Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol. Ther. 43, 53-76 (1989).
10. K. Nakamura, F. Goto, W. A. Ray, C. B. McAllister, E. Jacqz, G. R. Wilkinson, and R. A. Branch: Interhepatic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38, 402-408 (1985).
11. K. Chiba, K. Kobayashi, K. Manbe, M. Tani, T. Kamataki, and T. Ishizaki: Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J. Pharmacol. Exp. Ther. 266, 52-59 (1993).
12. J. D. Balian, N. Shukova, J. W. Harris, J. Hewett, L. Pickle, J. Goldstein, R. L. Woosley, and D. Flockhart: The hydroxylation of omeprazole correlates with 5-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther. 57, 662-669 (1995).
13. J. A. Goldstein, M. B. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. L. Raucy, J. M. Lasker, and B. I. Ghanayem: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33, 1743-1752 (1994).
14. S. A. Wrighton, J. C. Stevens, B. W. Becker, and M. Vandenbranden: Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and 5-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 306, 240-245 (1993).
15. M. F. S. De Morais, G. R. Wilkinson, J. Blaisdell, M. Nakamura, U. A. Meyer, and J. A. Goldstein: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422 (1994).
16. M. A. Leo, J. M. Lasker, J. L. Raucy, C. Kim, M. Black, and C. S. Lieber: Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. Arch. Biochem. Biophys. 269, 305-312 (1989).
17. D. E. Feierman and J. M. Lasker: Identification of CYP3A4 as the P450 enzyme responsible for the metabolism of fentanyl in human liver. Drug Metab. Dispos., in press, 1996.
18. L. S. Kaminsky, S. M. F. De Morais, M. B. Faletto, D. Dunbar, and J. A. Goldstein: Correlation of human P4502C substrate specificities with primary structure: warfarin as a probe. Mol. Pharmacol. 43, 234-239 (1993).
19. J. L. Raucy and J. M. Lasker: Isolation of P450 enzymes from human liver. Methods Enzymol. 206, 577-587 (1991).
20. M. Iwasaki, R. Juvonen, R. Lindberg, and M. Negishi: Alteration of high and low spin equilibrium by a single mutation of amino acid 209 in mouse cytochrome P450. J. Biol. Chem. 266, 3380-3382 (1991).
21. Y. Yasukochi and B. S. S. Masters: Some properties of a detergent solubilized NADPH-cytochrome c (cytochrome P450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251, 5337-5344 (1976).
22. J. L. Raucy and J. M. Lasker: Human P450 enzymes associated with S-mephenytoin 4-hydroxylation polymorphisms. In "Human Drug Metabolism: From Molecular Biology to Man" (E. H. Jeffrey, ed.), pp. 23-33. CRC Press, Boca Raton, FL, 1993.
23. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275 (1951).
24. T. Omura and R. Sato: The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378 (1964).
25. M. A. Amantea and P. K. Narang: Improved procedure for quantitation of omeprazole and metabolites using reverse-phase high performance liquid chromatography. J. Chromatogr. 426, 216-222 (1988).
26. D. Pessayre, M. Tinel, D. Larrey, B. Cobert, C. Funck-Brentano, and G. Babany: Inactivation of cytochrome P-450 by a troleandomycin metabolite: protective role of glutathione. J. Pharmacol. Exp. Ther. 224, 685-691 (1983).
27. T. Andersson, C. G. Regardh, Y. C. Lou, Y. Zhang, M. L. Dahl, and L. Bertilsson: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 2, 25-31 (1992).
28. T. Andersson and P.-O. Lagerstrøm: High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism. J. Chromatogr. 619, 291-297 (1993).
29. P. B. Watkins: Noninvasive tests for CYP3A enzymes. Pharmacogenetics 4, 171-184 (1994).